Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, T-Cell

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Dose -1：0.1×10E+6/kg Dose 1：0.25×10E+6/kg Dose 2：0.5×10E+6/kg Dose 3：1.0×10E+6/kg Dose 4：2.0×10E+6/kg

CD147- CAR T cells

Shenmiao Yang, MD.

Xiaojun Huang, MD. PhD.

The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.

CD147 has been demonstrated higher and relatively specific expression on T cell non-Hodgkin's lymphoma. Preclinical studies have shown that CAR T cells targeting CD147 antigen can continuously eliminate Jurkat T-cell lymphoma in mice and extend survival without severe adverse events including hemolysis. Preliminary investigation of CD147-CAR T cells in solid tumors has started and shown an acceptable safety profile. The safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

A Pioneering Study on the Safety and Efficacy of CD147-Chimeric Antigen Receptor (CAR) T Cells in Patients With Relapsed or Refractory T-cell Non-Hodgkin's Lymphoma

The highest dose that does not cause unacceptable side effects.

Side effects serious enough to prevent an increase in dose.

Overall response rate (ORR) evaluated according to the Lugano2014 criteria

Complete response rate (CR) evaluated according to the Lugano2014 criteria

Peking University People's Hospital

Prof.

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Liver Extracts

Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery

Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.

CD147-CART

Zhi-Nan Chen, PhD

Kaishan Tao, Dr

This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells by hepatic artery infusions in patients with advanced hepatocellular carcinoma.

Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART). CAR-T cells are expanded in culture and returned to the patient by hepatic artery infusion at specific cell doses. Four CD147-CART doses patient are planned at 1-week intervals. Tumor biopsies will be obtained at the time of the initial diagnostic angiogram and during the first infusion session. Serum cytokine level and CAR-T cell number will be measured in whole treatment session.

A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma

An Open-label, Dose Escalation Clinical Study to Access the Safety and Clinical Activity of CD147-targeted CART by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma

To assess the safety of CD147-CART (anti-CD147 CAR-T cell) hepatic artery infusions (HAI) for very advanced hepatocellular carcinoma which measured by number and type of adverse events.

To determine the dose limited toxicity (DLT) and maximum tolerated dose (MTD) of CD147-CART hepatic artery infusions.

To evaluate treatment response of CD147-CART hepatic artery infusions for very advanced hepatocellular carcinoma.

Quantification of CD147-CART cells in blood samples.

Xijing Hospital

Director of National Translational Science Center for Molecular Medicine

Symptoms and General Pathology

Recurrence

Glioma

Glioblastoma

Disease Attributes

Astrocytoma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neuroepithelioma

CD147-CAR modified T cells, intracavity injection, 3+3 design with de-escalation in half step, every 7 days for 3 weeks

Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.

Zhinan Chen, PhD

Zhou Fei, Dr

This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.

Patients autologous T cells are activated and then engineered to express chimeric antigen receptors (CARs) specific for CD147(CD147-CART). CAR-T cells are expanded in culture and returned to the patient by Ommaya Reservoir at specific cell doses. Three CD147-CART doses patient are planned at 1-week intervals. Serum cytokine level and CAR-T cell number will be measured in whole treatment session.

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

A Clinical Study to Investigate the Safety, Tolerance and Efficacy Evaluation of Single-centre, Open-label of Local Treatment of CD147-CART in Recurrent Glioblastoma.

To assess the safety and tolerability of CD147-CART (anti-CD147 CAR-T cell) for glioma which measured by number and type of adverse events.

To determine the dose limited toxicity (DLT) and maximum tolerated dose (MTD) of CD147-CART.

To evaluate treatment response of CD147-CART for glioma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma	NCT05013372	T-cell Non-Hodg...	CD147- CAR T ce...	18 Years - 65 Years	Peking University People's Hospital
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma	NCT05013372	T-cell Non-Hodg...	CD147- CAR T ce...	18 Years - 65 Years	Peking University People's Hospital
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma	NCT03993743	Advanced Hepato...	CD147-CART	18 Years - 65 Years	Xijing Hospital
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma	NCT05013372	T-cell Non-Hodg...	CD147- CAR T ce...	18 Years - 65 Years	Peking University People's Hospital
A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma	NCT03993743	Advanced Hepato...	CD147-CART	18 Years - 65 Years	Xijing Hospital
CD147-CART Cells in Patients With Recurrent Malignant Glioma.	NCT04045847	Recurrent Gliob... CD147 Positive	CD147-CART	18 Years - 65 Years	Xijing Hospital

Spots Global Cancer Trial Database for cd147

Every month we try and update this database with for cd147 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cd147

Every month we try and update this database with for cd147 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cd147 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.